GlassScriptPhysician profile
Asma Moussaoui
NPI 1720424898
$4,402.77
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $1,318 · 2021: $2,047 · 2022: $257 · 2023: $24.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.17 | 2021-2022 | |
| Allergan, INC. | $643.71 | 2019-2021 | |
| Amgen INC. | $359.28 | 2019-2021 | |
| Emd Serono, INC. | $320.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $218.89 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $217.47 | 2020-2021 | |
| Csl Behring | $141.77 | 2019-2020 | |
| Mdd US Operations, LLC | $141.09 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $137.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $132.61 | 2021-2023 | Andexxa |
| Biohaven Pharmaceuticals, INC. | $132.55 | 2021 | |
| Neurocrine Biosciences, INC. | $93.00 | 2020-2022 | |
| Ucb, INC. | $92.13 | 2019-2021 | |
| Genzyme Corporation | $72.18 | 2019-2020 | |
| Silk Road Medical, INC. | $69.26 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $64.97 | 2020-2021 | |
| Biogen, INC. | $60.51 | 2019-2020 | |
| Horizon Therapeutics Plc | $55.76 | 2021 | |
| Lilly USA, LLC | $55.24 | 2020-2021 | |
| Lundbeck LLC | $55.04 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $48.78 | 2020 | |
| Neurelis, INC. | $47.15 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $43.56 | 2019-2021 | |
| Ge Healthcare | $42.53 | 2020 | |
| Mallinckrodt Enterprises LLC | $40.09 | 2019 | |
| Sk Life Science, INC. | $38.42 | 2020 | |
| Adamas Pharmaceuticals, INC. | $33.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.91 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $19.14 | 2019 | |
| Boston Scientific Corporation | $14.13 | 2019 | |
| Celgene Corporation | $13.20 | 2021 | |
| Zyla Life Sciences, INC. | $13.20 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Moussaoui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.